Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus.

Jereczek-Fossa, Barbara A; Marvaso, Giulia; Zaffaroni, Mattia; Gugliandolo, Simone Giovanni; Zerini, Dario; Corso, Federica; Gandini, Sara; Alongi, Filippo; Bossi, Alberto; Cornford, Philip; De Bari, Berardino; Fonteyne, Valérie; Hoskin, Peter; Pieters, Bradley R; Tree, Alison C; Arcangeli, Stefano; Fuller, Donald B; Franzese, Ciro; Hannoun-Levi, Jean-Michel; Janoray, Guillaume; ... (2021). Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. Cancer treatment reviews, 98, p. 102206. Elsevier 10.1016/j.ctrv.2021.102206

[img] Text
1-s2.0-S0305737221000542-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (4MB) | Request a copy

BACKGROUND AND PURPOSE

Between 30% and 47% of patients treated with definitive radiotherapy (RT) for prostate cancer are at risk of intraprostatic recurrence during follow-up. Re-irradiation with stereotactic body RT (SBRT) is emerging as a feasible and safe therapeutic option. However, no consensus or guidelines exist on this topic. The purpose of this ESTRO ACROP project is to investigate expert opinion on salvage SBRT for intraprostatic relapse after RT.

MATERIALS AND METHODS

A 40-item questionnaire on salvage SBRT was prepared by an internal committee and reviewed by a panel of leading radiation oncologists plus a urologist expert in prostate cancer. Following the procedure of a Delphi consensus, 3 rounds of questionnaires were sent to selected experts on prostate re-irradiation.

RESULTS

Among the 33 contacted experts, 18 (54.5%) agreed to participate. At the end of the final round, participants were able to find consensus on 14 out of 40 questions (35% overall) and major agreement on 13 questions (32.5% overall). Specifically, the consensus was reached regarding some selection criteria (no age limit, ECOG 0-1, satisfactory urinary flow), diagnostic procedures (exclusion of metastatic disease, SBRT target defined on the MRI) and therapeutic approach (no need for concomitant ADT, consideration of the first RT dose, validity of Phoenix criteria for salvage SBRT failure).

CONCLUSION

While awaiting the results of ongoing studies, our ESTRO ACROP Delphi consensus may serve as a practical guidance for salvage SBRT. Future research should address the existing disagreements on this promising approach.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Shelan, Mohamed

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1532-1967

Publisher:

Elsevier

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

16 Jun 2021 14:11

Last Modified:

22 Jun 2021 01:33

Publisher DOI:

10.1016/j.ctrv.2021.102206

PubMed ID:

33965893

Uncontrolled Keywords:

Delphi consensus Recurrent prostate cancer Salvage radiotherapy Stereotactic body radiotherapy

BORIS DOI:

10.48350/156513

URI:

https://boris.unibe.ch/id/eprint/156513

Actions (login required)

Edit item Edit item
Provide Feedback